94,912 Shares in Pfizer Inc. $PFE Acquired by Hayek Kallen Investment Management

Key Points

• Hayek Kallen Investment Management acquired 94,912 Pfizer shares during the second quarter, valued at approximately $2.29 million. Institutional investors collectively own 68.36% of Pfizer’s outstanding stock.
• The FDA approved Pfizer and BioNTech’s updated 2026–2027 COVID-19 vaccine targeting the XFG variant, with shipments beginning immediately. The approval could support seasonal revenue, though future vaccine demand remains uncertain.
• Pfizer reported quarterly earnings of $0.77 per share and revenue of $15.03 billion, exceeding analyst expectations. Despite a 6.1% dividend yield, analysts maintain a consensus “Hold” rating with an average price target of $28.28.

Hayek Kallen Investment Management acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 94,912 shares of the biopharmaceutical company's stock, valued at approximately $2,285,000.

Other institutional investors also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Keb Asset Management LLC acquired a new stake in Pfizer during the second quarter worth approximately $26,000. HFM Investment Advisors LLC raised its holdings in Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 427 shares in the last quarter. Evolution Wealth Management Inc. lifted its position in shares of Pfizer by 132.2% during the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 566 shares during the period. Finally, Abound Financial LLC bought a new stake in shares of Pfizer during the 4th quarter valued at $31,000. Institutional investors own 68.36% of the company's stock.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The U.S. Food and Drug Administration approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COVID-19 vaccine. The updated Comirnaty formula is intended for adults 65 and older and younger individuals with qualifying health risks, with shipments beginning immediately. The approval supports Pfizer’s ability to compete in the upcoming respiratory-virus season and could provide seasonal revenue support. Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
• Positive Sentiment: The FDA also approved updated COVID-19 vaccines from Moderna and Novavax-Sanofi, following guidance to target the dominant XFG variant. Pfizer’s immediate distribution and extensive real-world safety record may help preserve its position in the U.S. vaccine market, although demand remains difficult to forecast. US FDA approves updated COVID vaccines for 2026-27 season

Analysts Set New Price Targets

Several research firms recently weighed in on PFE. UBS Group reaffirmed a "neutral" rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Wolfe Research restated an "underperform" rating and issued a $26.00 target price on shares of Pfizer in a research report on Thursday, May 14th. Guggenheim cut their price target on shares of Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. Cantor Fitzgerald reiterated a "neutral" rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus target price of $28.28.

Pfizer Stock Down 1.0%

Shares of NYSE PFE opened at $28.00 on Friday. The company has a market cap of $159.62 billion, a price-to-earnings ratio of 36.85 and a beta of 0.34. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 12 month low of $23.58 and a 12 month high of $28.75. The stock has a 50-day moving average price of $25.49 and a two-hundred day moving average price of $26.29.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same period last year, the company posted $0.78 EPS. The firm's quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer's dividend payout ratio (DPR) is presently 226.32%.

Pfizer Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source